Edition:
United Kingdom

People: Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

336.93USD
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
$336.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
330,208
52-wk High
$543.50
52-wk Low
$281.89

Aberman, Michael 

Dr. Michael Aberman, M.D., is Senior Vice President - Strategy and Investor Relation of the Company. He served as Vice President, Strategy and Investor Relations. Prior to joining the Company, he spent six years as a Wall Street analyst covering the biotechnology industry. From March 2006 until joining the Company, he was Director and Senior Biotechnology Analyst at Credit Suisse. Prior to that, from March 2004 to March 2006, he worked as a Biotechnology Analyst at Morgan Stanley, Inc. From February 2002 to March 2004, Dr. Aberman was Director of Business Development at Antigenics Inc., an oncology-focused biotechnology company. Dr. Aberman received his M.D. with honors from the University of Toronto and his M.B.A. from the Wharton School of the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

P. Roy Vagelos

13,240,600

Leonard Schleifer

28,337,500

Robert Landry

5,164,730

Daniel Van Plew

2,188,990

Neil Stahl

10,985,400

Joseph LaRosa

--
As Of  31 Dec 2016